Scientific
MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis
These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.
MK5 Proteome Network Type I Analysis

Type 1 network in which we propagated the absolute log regulation ratio abs(log(r/g)). We used the filtered lowest boundary of the confidence interval for the microarray measurement based and used the high confidence interaction map. Because type-I networks tend to favour highly connected proteins we tested a normalisation scheme in which we would run the network once with real values (the measured column) and once with simulated values where each measured point is set to 1 instead of the actual signal (the expected column). Afterwards we divided the measured value by the expected value. This normalisation scheme works to a certain extend but will lead to a variance that is directly related to the connectivity of each protein. In the end we dropped the use of Type-I networks due to the many technical problems they pose.
Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Rank Gene description measured expected final Hugo
Results: HTML CSV LaTeX
Showing element 1 to 50 of 3206 in total

\def\wcA{0.14285714285714\textwidth}
\def\wcB{0.14285714285714\textwidth}
\def\wcC{0.14285714285714\textwidth}
\def\wcD{0.14285714285714\textwidth}
\def\wcE{0.14285714285714\textwidth}
\def\wcF{0.14285714285714\textwidth}
\begin{longtable}{|c|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
measured\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
expected\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
final\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
Hugo\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PROTEIN CGI-126 (PROTEIN HSPC155). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.790808\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.682179\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.159238264\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
UFC1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RAD50-INTERACTING PROTEIN 1. \vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
1.28125\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
1.1674\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.097524413\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
RINT1\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
3\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RHO-RELATED BTB DOMAIN-CONTAINING PROTEIN 2 (DELETED IN BREAST CANCER 2 GENE PROTEIN) (P83). \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
RHOBTB2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
4\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
3.66001\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3.3348\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.097520091\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
5\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"NADH-UBIQUINONE OXIDOREDUCTASE 18 KDA SUBUNIT, MITOCHONDRIAL PRECURSOR (EC 1.6.5.3) (EC 1.6.99.3) (COMPLEX I-18 KDA) (CI-18 KDA) (COMPLEX I- AQDQ) (CI-AQDQ). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.489705\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.74385\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.658338375\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NDUFS4\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
6\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CHROMATIN ACCESSIBILITY COMPLEX PROTEIN 1 (CHRAC-1) (CHRAC-15) (HUCHRAC15) (DNA POLYMERASE EPSILON SUBUNIT P15). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.590586\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.969328\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.609273641\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CHRAC1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
7\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ADIPONECTIN RECEPTOR 2. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.252763\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.428531\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.589835975\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ADIPOR2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
8\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ODD-SKIPPED RELATED 1; ODZ (ODD OZ/TEN-M) RELATED 1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.281519\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.487701\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.577236873\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
OSR1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
9\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DNA POLYMERASE EPSILON P12 SUBUNIT (DNA POLYMERASE EPSILON SUBUNIT 4). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.803534\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.40271\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.572843995\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
POLE4\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
10\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PROTEIN X 0004. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.271296\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.5\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.542592\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
ATPBD1C\vspace{3pt}}\\\cline{1-4}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
11\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
XPA BINDING PROTEIN 1; MBD2 INTERACTOR PROTEIN; PUTATIVE ATP(GTP)-BINDING PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.813888\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.5\vspace{3pt}}&&\parbox{\wcF}{\vspace{3pt}\noindent
XAB1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
12\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HBS1-LIKE. \vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.250879\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.5\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.501758\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
HBS1L\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
13\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HOMEOBOX PROTEIN HLX1 (HOMEOBOX PROTEIN HB24). \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
HLX\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
14\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NUCLEAR TRANSCRIPTION FACTOR Y SUBUNIT BETA (NF-Y PROTEIN CHAIN B) (NF-YB) (CCAAT-BINDING TRANSCRIPTION FACTOR SUBUNIT A) (CBF-A) (CAAT- BOX DNA BINDING PROTEIN SUBUNIT B). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.439158\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.912166\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.481445263\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NFYB\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
15\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GROWTH FACTOR RECEPTOR-BOUND PROTEIN 2 (GRB2 ADAPTER PROTEIN) (SH2/SH3 ADAPTER GRB2) (ASH PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1.95189\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
4.10415\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.475589342\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
GRB2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
16\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SERINE/THREONINE-PROTEIN KINASE NEK2 (EC 2.7.1.37) (NIMA-RELATED PROTEIN KINASE 2) (NIMA-LIKE PROTEIN KINASE 1) (HSPK 21). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.106175\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.22325\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.475587906\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NEK2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
17\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0856348\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.180231\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.475139127\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\cline{1-1}\cline{3-6}
\parbox{\wcA}{\vspace{3pt}\noindent
18\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
0.0773877\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.162874\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.475138451\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
FAM49B\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
19\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
E2A-PBX1-ASSOCIATED PROTEIN; PUTATIVE 47 KDA PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.310118\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.652691\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.475137546\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ANKS1B\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
20\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NEURON NAVIGATOR 1; NEURON NAVIGATOR-1; PORE MEMBRANE AND/OR FILAMENT INTERACTING LIKE PROTEIN 3. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.149206\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.314027\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.475137488\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NAV1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
21\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NEURON NAVIGATOR 3; PORE MEMBRANE AND/OR FILAMENT INTERACTING LIKE PROTEIN 1; STEERIN 3. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.150125\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.315963\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.475134747\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NAV3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
22\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NEURON NAVIGATOR 2 ISOFORM L; RETINOIC ACID INDUCIBLE IN NEUROBLASTOMA; PORE MEMBRANE AND/OR FILAMENT INTERACTING LIKE PROTEIN 2; HELICASE HELAD1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.192159\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.404444\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.475118929\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NAV2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
23\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GRB2-RELATED ADAPTOR PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1.4649\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3.08715\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.47451533\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
GRAP\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
24\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.229891\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.5\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.459782\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CNOT10\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
25\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DNA-REPAIR PROTEIN COMPLEMENTING XP-G CELLS (XERODERMA PIGMENTOSUM GROUP G COMPLEMENTING PROTEIN) (DNA EXCISION REPAIR PROTEIN ERCC-5). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.364125\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.853699\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.426526211\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ERCC5\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
26\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DOCKING PROTEIN 2 (P56(DOK-2)) (DOWNSTREAM OF TYROSINE KINASE 2). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0954445\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.223986\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.42611815\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
DOK2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
27\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TYROSINE-PROTEIN KINASE FRK (EC 2.7.1.112) (NUCLEAR TYROSINE PROTEIN KINASE RAK). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.643425\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.50997\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.426117737\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
FRK\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
28\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DOK-LIKE PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0753031\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.176719\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.426117735\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
29\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DOCKING PROTEIN 1 (P62(DOK)) (DOWNSTREAM OF TYROSINE KINASE 1) (PP62). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0754466\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.177056\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.426117161\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
DOK1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
30\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TATA-BINDING PROTEIN-ASSOCIATED PHOSPHOPROTEIN (DOWN-REGULATOR OF TRANSCRIPTION 1) (DR1 PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.263027\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.621928\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.422921946\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
DR1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
31\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
WISKOTT-ALDRICH SYNDROME PROTEIN (WASP). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1.97356\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
4.68345\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.421390214\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
WAS\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
32\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (EC 2.7.1.112) (P60-SRC) (C-SRC). \vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.141847\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.33698\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.420935961\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
33\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TYROSINE-PROTEIN KINASE HCK (EC 2.7.1.112) (P59-HCK/P60-HCK) (HEMOPOIETIC CELL KINASE). \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
HCK\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
34\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PROTO-ONCOGENE C-CRK (P38) (ADAPTER MOLECULE CRK). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.142264\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.337971\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.420935524\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CRK\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
35\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CRK-LIKE PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.142003\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.337351\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.420935465\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CRKL\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
36\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (EC 2.7.1.112) (P150) (C-ABL). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.143775\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.341561\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.42093506\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ABL1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
37\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FGR (EC 2.7.1.112) (P55-FGR) (C-FGR). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.14242\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.338342\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.42093503\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
FGR\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
38\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TYROSINE-PROTEIN KINASE ABL2 (EC 2.7.1.112) (TYROSINE KINASE ARG). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.143514\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.340942\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.420933766\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ABL2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
39\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (EC 2.7.1.112) (P59-FYN) (SYN) (SLK). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.14268\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.338961\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.420933382\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
FYN\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
40\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GRB2-RELATED ADAPTOR PROTEIN 2 (GADS PROTEIN) (GROWTH FACTOR RECEPTOR BINDING PROTEIN) (GRBLG) (GRF40 ADAPTOR PROTEIN) (GRF-40) (GRB-2-LIKE PROTEIN) (GRB2L) (GRBX) (P38) (HEMATOPOIETIC CELL-ASSOCIATED ADAPTOR PROTEIN GRPL) (ADAPTER PROTEIN GRID) (SH3-SH2-\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.160294\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.380812\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.420926862\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
GRAP2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
41\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CCAAT DISPLACEMENT PROTEIN (CDP) (CUT-LIKE 1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.187173\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.444789\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.420813015\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CUTL1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
42\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HOMEOBOX PROTEIN CUX-2 (CUT-LIKE 2) (FRAGMENT). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.147881\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.35143\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.420797883\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CUTL2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
43\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NEURAL WISKOTT-ALDRICH SYNDROME PROTEIN (N-WASP). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1.66627\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3.96399\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.420351716\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
WASL\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
44\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF-4-ALPHA) (TRANSCRIPTION FACTOR HNF-4) (TRANSCRIPTION FACTOR 14). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.144656\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.346879\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.417021497\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HNF4A\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
45\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GROWTH ARREST AND DNA-DAMAGE-INDUCIBLE PROTEIN GADD45 GAMMA (CYTOKINE RESPONSIVE PROTEIN CR6). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.203633\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.488304\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.417020954\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
GADD45G\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
46\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HEPATOCYTE NUCLEAR FACTOR 4-GAMMA (HNF-4-GAMMA). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.117156\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.280936\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.417020247\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HNF4G\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
47\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GROWTH ARREST AND DNA-DAMAGE-INDUCIBLE PROTEIN GADD45 BETA (NEGATIVE GROWTH-REGULATORY PROTEIN MYD118) (MYELOID DIFFERENTIATION PRIMARY RESPONSE PROTEIN MYD118). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.173246\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.415438\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.417020109\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
GADD45B\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
48\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GROWTH ARREST AND DNA-DAMAGE-INDUCIBLE PROTEIN GADD45 ALPHA (DNA- DAMAGE INDUCIBLE TRANSCRIPT 1) (DDIT1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.174044\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.417352\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.417019686\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
GADD45A\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
49\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
FERRITIN HEAVY CHAIN (FERRITIN H SUBUNIT). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.788413\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.91686\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.411304425\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
FTH1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
50\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
FERRITIN LIGHT CHAIN (FERRITIN L SUBUNIT). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0515298\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.125329\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.411156237\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
FTL\vspace{3pt}}\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Hugo is the bloody hugo identifier as demanded by the BMC Bioinformatics idiots
- http://analysis.yellowcouch.org/